Verdiva Bio Announces Completion of Enrollment for EVOLVE-2 Phase 2b Study of VRB-101, a Potential Once-Weekly Oral GLP-1 Peptide Analog in Individuals with Obesity
Verdiva Bio Limited (“Verdiva Bio” or “the Company”) a clinical-stage biopharmaceutical company focused on developing innovative therapies for obesity and cardiometabolic disorders, today announced the completion of enrollment for its Phase 2b EVOLVE-2 clinical study of VRB-101, a once-weekly oral, cAMP-biased, GLP-1 peptide analog candidate for body weight reduction in people with overweight or obesity. The Company currently expects to report topline data from the study by the end of 2026.
